Literature DB >> 16266902

Molecular and biological characterization of three novel interleukin-6-dependent human myeloma cell lines.

Donata Verdelli1, Michela Mattioli, Sonia Fabris, Lucia Nobili, Daniela Intini, Silvana Guerneri, Katia Todoerti, Alberto Zanella, Giorgio Lambertenghi Deliliers, Luigia Lombardi, Antonino Neri.   

Abstract

BACKGROUND AND OBJECTIVES: Established human myeloma cell lines (HMCL) have significantly contributed to the investigation of the biological aspects of multiple myeloma. Our study reports the molecular and biological characterization of three novel interleukin-6 (IL-6)-dependent HMCL (CMA-01, CMA-02, CMA-03) established from the malignant plasma cells of myeloma patients with extramedullary disease. DESIGN AND METHODS: The immunophenotype, cell growth characteristics, IL-6 pathway, chromosomal alterations and gene expression profiles of the three HMCL were investigated.
RESULTS: The plasma cell origin of the three Epstein-Barr virus-negative HMCL was confirmed by immunophenotypic analysis. Cytogenetic and fluorescence in situ hybridization analyses revealed the presence of complex karyotypes with many numerical and structural chromosomal abnormalities. All three HMCL are positive for the t(8;14); CMA-01 and CMA-02 showed t(11;14) and t(14;16) translocations, respectively. The three HMCL grow slowly at a relatively low saturation density and depend on exogenous IL-6 for their survival and proliferation. The comparison of the gene expression profiles of the three HMCL versus those of the purified tumor plasma cells from which the cell lines were derived identified a set of differentially expressed genes mainly involved in the cell proliferation pathway. INTERPRETATION AND
CONCLUSIONS: Extensively characterized large HMCL panels that reflect the heterogeneity of the disease may improve our understanding of the pathogenetic events and clinical progression of multiple myeloma.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16266902

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  5 in total

1.  Patient with refractory multiple myeloma developing eosinophilia after lenalidomide treatment and lung cancer 9 months later: case report and review of the literature.

Authors:  Yasunobu Sekiguchi; Asami Shimada; Hidenori Imai; Mutsumi Wakabayashi; Keiji Sugimoto; Noriko Nakamura; Tomohiro Sawada; Norio Komatsu; Masaaki Noguchi
Journal:  Indian J Hematol Blood Transfus       Date:  2014-03-14       Impact factor: 0.900

2.  Establishment and exploitation of hyperdiploid and non-hyperdiploid human myeloma cell lines.

Authors:  Xin Li; Angela Pennisi; Fenghuang Zhan; Jeffrey R Sawyer; John D Shaughnessy; Shmuel Yaccoby
Journal:  Br J Haematol       Date:  2007-09       Impact factor: 6.998

3.  Overexpression of Annexin II affects the proliferation, apoptosis, invasion and production of proangiogenic factors in multiple myeloma.

Authors:  Hongyu Bao; Miao Jiang; Mingqing Zhu; Fei Sheng; Jia Ruan; Changgeng Ruan
Journal:  Int J Hematol       Date:  2009-07-08       Impact factor: 2.490

4.  An integrative genomic approach reveals coordinated expression of intronic miR-335, miR-342, and miR-561 with deregulated host genes in multiple myeloma.

Authors:  Domenica Ronchetti; Marta Lionetti; Laura Mosca; Luca Agnelli; Adrian Andronache; Sonia Fabris; Giorgio Lambertenghi Deliliers; Antonino Neri
Journal:  BMC Med Genomics       Date:  2008-08-13       Impact factor: 3.063

5.  Multiple myeloma-derived Jagged ligands increases autocrine and paracrine interleukin-6 expression in bone marrow niche.

Authors:  Michela Colombo; Serena Galletti; Gaetano Bulfamante; Monica Falleni; Delfina Tosi; Katia Todoerti; Elisa Lazzari; Leslie A Crews; Catriona H M Jamieson; Sara Ravaioli; Francesco Baccianti; Silvia Garavelli; Natalia Platonova; Antonino Neri; Raffaella Chiaramonte
Journal:  Oncotarget       Date:  2016-08-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.